Osteogenesis imperfecta

被引:931
作者
Rauch, F
Glorieux, FH
机构
[1] Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada
[2] McGill Univ, Montreal, PQ H3G 1A6, Canada
关键词
D O I
10.1016/S0140-6736(04)16051-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta is a genetic disorder of increased bone fragility, low bone mass, and other connective-tissue manifestations. The most frequently used classification outlines four clinical types, which we have expanded to seven distinct types. In most patients the disorder is caused by mutations in one of the two genes encoding collagen type 1, but in some individuals no such mutations are detectable. The most important therapeutic advance is the introduction of bisphosphonate treatment for moderate to severe forms of osteogenesis imperfecta. However, at present, the best treatment regimen and the long-term outcomes of bisphosphonate therapy are unknown. Although this treatment does not constitute a cure, it is an adjunct to physiotherapy, rehabilitation, and orthopaedic care. Gene-based therapy presently remains in the early stages of preclinical research.
引用
收藏
页码:1377 / 1385
页数:9
相关论文
共 131 条
[1]   Intravenous neridronate in adults with osteogenesis imperfecta [J].
Adami, S ;
Gatti, D ;
Colapietro, F ;
Fracassi, E ;
Braga, V ;
Rossini, M ;
Tatò, L .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (01) :126-130
[2]  
ALBRIGHT JA, 1981, CLIN ORTHOP RELAT R, P88
[3]   Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis [J].
Antoniazzi, F ;
Bertoldo, F ;
Mottes, M ;
Valli, M ;
Sirpresi, S ;
Zamboni, G ;
Valentini, R ;
Tato, L .
JOURNAL OF PEDIATRICS, 1996, 129 (03) :432-439
[4]  
Åström E, 1998, ACTA PAEDIATR, V87, P64
[5]   Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].
Åström, E ;
Söderhäll, S .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364
[6]   Osteogenesis imperfecta and intravenous pamidronate [J].
Banerjee, I ;
Shortland, GJ ;
Evans, WD ;
Gregory, JW .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (06) :562-563
[7]   Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: Indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17 [J].
Bank, RA ;
Robins, SP ;
Wijmenga, C ;
Breslau-Siderius, LJ ;
Bardoel, AFJ ;
Van der Sluijs, HA ;
Pruijs, HEH ;
TeKoppele, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1054-1058
[8]  
BEIGHTON P, 1985, CLIN GENET, V28, P69
[9]   Intravenous pamidronate treatment in osteogenesis imperfecta [J].
Bembi, B ;
Parma, A ;
Bottega, M ;
Ceschel, S ;
Zanatta, M ;
Martini, C ;
Ciana, G .
JOURNAL OF PEDIATRICS, 1997, 131 (04) :622-625
[10]   Marrow stromal stem cells [J].
Bianco, P ;
Robey, PG .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (12) :1663-1668